MedTrace Logo

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

NCT06618664 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 590

Last updated 2026-05-04

No results posted yet for this study

Summary

THis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.

Conditions

Interventions

DRUG

SHR-8068

SHR-8068: injection, 50 mg/10 mL, intravenous infusion

DRUG

Adebrelimab

Adebrelimab: injection, 600 mg/12 mL, intravenous infusion

DRUG

Bevacizumab

Bevacizumab: injection, 100 mg/4 mL, intravenous infusion

DRUG

Sintilimab

Sintilimab: injection, 100 mg/10 mL, intravenous infusion

DRUG

Atezolizumab injection

Atezolizumab injection.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-28
Primary Completion
2026-09-30
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618664 on ClinicalTrials.gov